Unique ID issued by UMIN | UMIN000002458 |
---|---|
Receipt number | R000002989 |
Scientific Title | Prospective study of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation |
Date of disclosure of the study information | 2009/09/08 |
Last modified on | 2017/09/12 09:59:44 |
Prospective study of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation
Prospective study of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation
Prospective study of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation
Prospective study of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation
Japan |
primary lung cancer
Radiology |
Malignancy
NO
The aim of this study is to evaluate the outcome of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer without pathologic confirmation.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
overall survival rate
progression-free survival rate, safety
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients with lung tumor less than 3cm in diameter and less than three lesions.
2) Patients unable to confirm pathological diagnosis.
3) Positive on FDG-PET except patients with GGO.
4) Apparent growth of lung tumor on CT.
5) Aged 20 years or more, 0-2 of ECOG performance status.
6) Patients must be consulted by surgeon.
7) Patients must be consulted by internal physician.
8) Able to make planning of radiotherapy within the regulation dose.
9) No history of radiation for chest.
10) PaO2 60 torr or more at room air, FEV1.0 700 ml or more.
1) Apparent interstitial pneumonia on chest X-ray.
2) Patinets with active infectious disease.
3) Patients with active other cancers.
4) Pregnant patients.
5) Patients with psychiatric disorders and unable to participate the study.
6) Patients now treated by steroids.
7) Patients who need oxygen inhalation.
8) Fever up.
65
1st name | |
Middle name | |
Last name | Hiroki Shirato |
Hokkaido University Graduate School of Medicine
Department of Radiology
North 15 West 7, Kita-ku, Sapporo, Japan
011-706-5977
shirato@med.hokudai.ac.jp
1st name | |
Middle name | |
Last name | Tetsuya Inoue |
Hokkaido University Graduate School of Medicine
Department of Radiology
North 15 West 7, Kita-ku, Sapporo, Japan
011-706-5977
t-inoue@med.hokudai.ac.jp
Hokkaido University Hospital
Research group for low-risk and high-dose radiotherapy by highly advanced technology
Japanese Governmental office
JAPAN
NO
北海道大学病院、他11施設
2009 | Year | 09 | Month | 08 | Day |
Unpublished
With a median follow-up period of 55 months, the 3-year overall survival rate was 83% (95%CI:71-91%). Grade 3 and 4 chronic adverse event was experienced in 8 and 1 patients, respectively.
Completed
2009 | Year | 08 | Month | 21 | Day |
2009 | Year | 09 | Month | 01 | Day |
2017 | Year | 08 | Month | 14 | Day |
2017 | Year | 09 | Month | 07 | Day |
2017 | Year | 09 | Month | 07 | Day |
2017 | Year | 12 | Month | 31 | Day |
We observe patients treated by stereotactic body radiotherapy, who were clinically diagnosed as primary lung cancer without pathologic confirmation.
2009 | Year | 09 | Month | 06 | Day |
2017 | Year | 09 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002989